Prostatype Genomics Management
Management criteria checks 2/4
Prostatype Genomics' CEO is Fredrik Rickman, appointed in Jan 2017, has a tenure of 8.5 years. directly owns 0.027% of the company’s shares, worth SEK9.75K. The average tenure of the management team and the board of directors is 2.6 years and 6.5 years respectively.
Key information
Fredrik Rickman
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 8.5yrs |
| CEO ownership | 0.03% |
| Management average tenure | 2.6yrs |
| Board average tenure | 6.5yrs |
Recent management updates
Recent updates
CEO
Fredrik Rickman
Mr. Fredrik Rickman has been Chief Executive Officer of Prostatype Genomics AB (publ) since 2017 and serves as its Managing Director. He has years of international life science industry experience in leadi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & MD | 8.5yrs | no data | 0.027% SEK 9.7k | |
| Chief Financial Officer | 1.8yrs | no data | no data | |
| Vice President Commercial operations | no data | no data | no data | |
| Chief Technology Officer | 2.7yrs | no data | no data | |
| Communications Director | 3.8yrs | no data | no data | |
| Chief Auditor | 3.1yrs | no data | no data | |
| Global Chief Medical Officer | 2.2yrs | no data | no data | |
| President of US operations | 2.5yrs | no data | no data | |
| QA & RA Manager | 2.5yrs | no data | no data | |
| Sales Director of EMEA | no data | no data | no data |
Experienced Management: PROGEN's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman of the Board | 8.5yrs | no data | no data | |
| Independent Director | 3.1yrs | no data | no data | |
| Independent Director | 6.5yrs | no data | 1.76% SEK 635.0k | |
| Independent Director | 7.5yrs | no data | 0.15% SEK 55.6k | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 1.7yrs | no data | 0.032% SEK 11.7k |
Experienced Board: PROGEN's board of directors are considered experienced (6.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/09 03:42 |
| End of Day Share Price | 2025/07/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prostatype Genomics AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Johan Unnerus | Redeye |